Aclasta 5 mg solution for infusion
Last Updated on eMC 27-Apr-2017 View document | Novartis Pharmaceuticals UK Ltd Contact details
Versions
- 27-Apr-2017 to Current
- 02-Aug-2016 to 27-Apr-2017
- 09-Dec-2015 to 02-Aug-2016
- 10-Jun-2015 to 09-Dec-2015
- 10-Mar-2015 to 10-Jun-2015
- 19-Jan-2015 to 10-Mar-2015
- 10-Jun-2014 to 19-Jan-2015
- 09-Sep-2013 to 10-Jun-2014
- 04-May-2012 to 09-Sep-2013
- 09-Feb-2012 to 04-May-2012
- 19-Jul-2011 to 09-Feb-2012
- 26-May-2010 to 19-Jul-2011
- 06-Aug-2009 to 26-May-2010
- 11-Nov-2008 to 06-Aug-2009
- 23-Oct-2007 to 11-Nov-2008
- 06-Jul-2006 to 23-Oct-2007
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 27-Apr-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 02-Aug-2016 and displayed until 27-Apr-2017
Reasons for adding or updating:
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 09-Dec-2015 and displayed until 02-Aug-2016
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 10-Jun-2015 and displayed until 09-Dec-2015
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 10-Mar-2015 and displayed until 10-Jun-2015
Reasons for adding or updating:
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - driving and using machines
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 19-Jan-2015 and displayed until 10-Mar-2015
Reasons for adding or updating:
- Correction of spelling/typing errors
Updated on 10-Jun-2014 and displayed until 19-Jan-2015
Reasons for adding or updating:
- Correction of spelling/typing errors
Updated on 09-Sep-2013 and displayed until 10-Jun-2014
Reasons for adding or updating:
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - use in children/adolescents
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Change to other sources of information section
- Change to information for healthcare professionals
Updated on 04-May-2012 and displayed until 09-Sep-2013
Reasons for adding or updating:
- Change to dosage and administration
Updated on 09-Feb-2012 and displayed until 04-May-2012
Reasons for adding or updating:
- Change to date of revision
- Change of contra-indications
- Change to MA holder contact details
Updated on 19-Jul-2011 and displayed until 09-Feb-2012
Reasons for adding or updating:
- Change to date of revision
- Change to side-effects
Updated on 26-May-2010 and displayed until 19-Jul-2011
Reasons for adding or updating:
- Change to date of revision
- Change to side-effects
- Change to dosage and administration
Updated on 06-Aug-2009 and displayed until 26-May-2010
Reasons for adding or updating:
- Change to, or new, use for medicine
- Change to warnings or special precautions for use
- Change to side-effects
- Changes to therapeutic indications
Updated on 11-Nov-2008 and displayed until 06-Aug-2009
Reasons for adding or updating:
- Change to, or new, use for medicine
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 23-Oct-2007 and displayed until 11-Nov-2008
Reasons for adding or updating:
- Change to, or new, use for medicine
Updated on 06-Jul-2006 and displayed until 23-Oct-2007
Reasons for adding or updating:
- New PIL for new product
Novartis Pharmaceuticals UK Ltd
Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
+44 (0)1276 692 255
+44 (0)1276 698 370
+44 (0)845 741 9442
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue